Valeant ups bid for Dendreon's Provenge to $400m
This article was originally published in Scrip
Valeant Pharmaceuticals has increased its bid by more than $100m to acquire the personalized prostate cancer immunotherapy Provenge (sipuleucel-T) and other Dendreon assets for $400m.
You may also be interested in...
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
Strategy of focusing immunotherapy on urologists and earlier stage prostate cancer is paying off, says CEO James Caggiano, as Dendreon becomes a standalone company under Chinese conglomerate Sanpower
Troubled Valeant has started the new year by announcing the sale of some $2.1bn in assets to get funds to hone down its operations and to start easing its debt burden amid allegations of unethical practices.